Mylan ramps up manufacturing of hydroxycholoroquin
Post# of 127098
(Total Views: 119)
Posted On: 03/19/2020 7:57:41 PM
Mylan ramps up manufacturing of hydroxycholoroquine sulfate tablets
Mylan announced its continued commitment to do its part in support of public health needs amidst the evolving COVID-19 pandemic. The company continues to focus its efforts on protecting its employees, producing critically needed medications, and turning its scientific and operational expertise towards identifying additional ways it may be able to assist in the massive prevention, diagnosis and treatment efforts needed to counter the spread of COVID-19.
For example, in the immediate term, Mylan has restarted production of hydroxychloroquine sulfate tablets at its West Virginia manufacturing facility in the U.S. to meet the potential for increased demand resulting from potential effectiveness of the product in treating COVID-19. Mylan's hydroxychloroquine sulfate tablets are approved by the U.S. Food and Drug Administration for the treatment of malaria, lupus erythematosus and rheumatoid arthritis.
Although the product is not currently approved for use in the treatment of COVID-19, it is listed by the World Health Organization as a drug under investigation for efficacy against the coronavirus. The company is also taking steps to initiate production of this product outside the U.S. in the coming weeks.
Mylan expects to be in a position to begin supplying product by mid-April, and with the active pharmaceutical ingredient that it currently has available, will be able to ramp up manufacturing to provide 50M tablets to potentially treat a total of more than 1.5M.
The potential use of this medicine for COVID-19 related treatment is pending additional FDA and other regulatory body guidance.
Read more at:
https://thefly.com/landingPageNews.php?id=3056197
Stock>>>
https://stockcharts.com/h-sc/ui?s=MYL&p=D...1860898997
Mylan announced its continued commitment to do its part in support of public health needs amidst the evolving COVID-19 pandemic. The company continues to focus its efforts on protecting its employees, producing critically needed medications, and turning its scientific and operational expertise towards identifying additional ways it may be able to assist in the massive prevention, diagnosis and treatment efforts needed to counter the spread of COVID-19.
For example, in the immediate term, Mylan has restarted production of hydroxychloroquine sulfate tablets at its West Virginia manufacturing facility in the U.S. to meet the potential for increased demand resulting from potential effectiveness of the product in treating COVID-19. Mylan's hydroxychloroquine sulfate tablets are approved by the U.S. Food and Drug Administration for the treatment of malaria, lupus erythematosus and rheumatoid arthritis.
Although the product is not currently approved for use in the treatment of COVID-19, it is listed by the World Health Organization as a drug under investigation for efficacy against the coronavirus. The company is also taking steps to initiate production of this product outside the U.S. in the coming weeks.
Mylan expects to be in a position to begin supplying product by mid-April, and with the active pharmaceutical ingredient that it currently has available, will be able to ramp up manufacturing to provide 50M tablets to potentially treat a total of more than 1.5M.
The potential use of this medicine for COVID-19 related treatment is pending additional FDA and other regulatory body guidance.
Read more at:
https://thefly.com/landingPageNews.php?id=3056197
Stock>>>
https://stockcharts.com/h-sc/ui?s=MYL&p=D...1860898997
(0)
(0)